Edward L. Barnes, MD, MPH, assistant professor in the UNC Division of Gastroenterology and Hepatology, is lead author of a new manuscript published online ahead of print in the Journal of Clinical Gastroenterology. Millie D. Long, MD, MPH, associate professor in the Division of Gastroenterology and Hepatology, is the manuscript’s senior author.
Edward L. Barnes, MD, MPH, assistant professor in the UNC Division of Gastroenterology and Hepatology, is lead author of a new manuscript published online ahead of print in the Journal of Clinical Gastroenterology. Millie D. Long, MD, MPH, associate professor, is the manuscript’s senior author.
The manuscript, “Older Adult Patients Use More Aminosalicylate Monotherapy Compared to Younger Patients with Inflammatory Bowel Disease: TARGET-IBD,” analyzed more than 2,900 patients across 34 academic or community sites in the U.S. between July 1, 2017 and February 18, 2020. Younger patients with this diagnosis were significantly more likely to use anti-tumor necrosis alpha (anti-TNF) monotherapy compared to older patients with IBD.
“Understanding patterns between these two populations of Crohn’s disease and ulcerative colitis patients is critical to informing future evaluations and clinical outcomes,” said Dr. Barnes. “Given the aging population in the United States, and the host of issues that come along with treating older patients, utilization patterns have long-term implications for IBD control.”
TARGET-IBD is an active 5-year longitudinal, observational study of more than 4,400 adult and pediatric patients with IBD receiving usual care from 36 academic and community centers throughout the U.S. Real-world data is collected retrospectively for three years from the time of the patient’s date of consent and patients are also followed prospectively for a minimum of five years. The robust TARGET-IBD cohort allows for the collection of effectiveness and safety data upon new drug approvals.